Mohsen Agharazii

Mohsen Agharazii

Auto-generated profile, based on publicly available information

Mohsen Agharazii

Université Laval

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2014 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
MAMohsen Agharazii
Mohsen Agharazii
RSRonald St-Louis
Ronald St-Louis
AGAlexandra Gautier-Bastien
Alexandra Gautier-Bastien
RURoth-Visal Ung
Roth-Visal Ung
SMSophie Mokas
Sophie Mokas
DRDarren E. Richard
Darren E. Richard
Vascular calcification, a regulated process in chronic kidney disease (CKD), requires vascular smooth muscle cell (VSMC) differentiation into osteoblast-like cells. This phenomenon can be enhanced by inflammatory cytokines and production of reactive oxygen species (ROS). In CKD rats with vascular calcification, we investigated whether inflammatory cytokines, ROS generation, and downstream signaling events are associated with CKD-related vascular calcification. CKD was induced in male Wistar rats by renal mass ablation and vascular calcification was induced with a high calcium–phosphate diet and vitamin D supplementation (Ca/P/VitD). At week 3–6, hemodynamic parameters were determined and thoracic aorta was harvested for assessment of vascular calcification, macrophage infiltration, cytokines expression, VSMC differentiation, ROS generation, and related signaling pathway activation. CKD rats treated with Ca/P/VitD developed medial calcification of thoracic aorta and increased pulse pressure and aortic pulse wave velocity. VSMC differentiation was confirmed by increased bone morphogenetic protein-2 and osteocalcin expression and reduced α-smooth muscle actin expression. The expression of interleukin-1β, interleukin-6, and tumor necrosis factor were also increased. The expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits p22phox and p47phox were increased, whereas the expression of antioxidant enzymes (SOD1, SOD2, Gpx1, and Prdx1) was reduced in CKD + Ca/P/VitD rats. Oxidized peroxiredoxin, a sensor of ROS generation, was significantly increased and ROS-sensitive signaling pathways were activated in the aorta from CKD + Ca/P/VitD rats. This study demonstrates a relationship between inflammation/ROS and arterial calcification in CKD and contributes to understanding of the complex pathways that mediate arterial calcification in CKD patients.

1 October 2005 in Journal Of Hypertension
Verified
Journal Article
Closed access
PLPhilippe Lavoie
Philippe Lavoie
GRGeneviève Robitaille
Geneviève Robitaille
MAMohsen Agharazii
Mohsen Agharazii
SLSteve Ledbetter
Steve Ledbetter
MLMarcel Lebel
Marcel Lebel
RLRichard Larivière
Richard Larivière
We investigate the role of transforming growth factor-β (TGF-β) in hypertension and renal failure progression in uremic rats, and whether it modulates the endothelin (ET) system. Following renal mass reduction, uremic rats (Nx) received the pan-specific TGF-β neutralizing antibody 1D11 (0.5 mg/kg, three times/week), the isotype control antibody 13C4 or the AT1 antagonist losartan (10 mg/kg per day) for 6 weeks. Before treatment, the blood pressure was higher in Nx rats and increased further over time in Nx + 13C4 rats. At the end of the study, Nx + 13C4 rats exhibited increased serum creatinine, proteinuria and renal expression and excretion of TGF-β1 and ET-1. ET-1 concentrations were greater in vascular and renal tissues, whereas the ETB receptor expression was reduced. Renal injuries were comprised of blood vessel hypertrophy, glomerular sclerosis, tubular atrophy and interstitial fibrosis, which was associated with increased α-smooth muscle actin expression. Treatment of uremic rats with the 1D11 antibody attenuated the increase in blood pressure and the decline in renal function. Losartan normalized the blood pressure and significantly attenuated the increase in serum creatinine and proteinuria. However, both treatments prevented renal TGF-β1 and ET-1 overexpression, and prevented all renal histological injuries. The 1D11 antibody only improved ETB receptor expression. Neutralization of TGF-β attenuates hypertension and renal failure progression in uremic animals, in part, by preventing renal injury processes. These effects may be related to the modulation of the ET system, preventing renal ET-1 overproduction and the reduction of ETB receptor expression. Our data also suggest that TGF-β1 is involved, at least in part, in the pathological effects related to angiotensin II in chronic renal failure.

1 September 2016 in Kidney International
Verified
Journal Article
Closed access
SMSophie Mokas
Sophie Mokas
RLRichard Larivière
Richard Larivière
LLLaurent Lamalice
Laurent Lamalice
SGStéphane Gobeil
Stéphane Gobeil
DCDavid N. Cornfield
David N. Cornfield
DRDarren E. Richard
Darren E. Richard

1 February 2004 in Kidney International
Verified
Journal Article
Closed access
PDF file
Gerard M. LondonGerard M. London
Gerard M. London
BPBruno Pannier
Bruno Pannier
MAMohsen Agharazii
Mohsen Agharazii
AGAlain P. Guerin
Alain P. Guerin
FVFrancis H.M. Verbeke
Francis H.M. Verbeke
SMSylvain J. Marchais
Sylvain J. Marchais

9 January 2024 in Circulation
Verified
Journal Article
Closed access
GHGregory Hundemer
Gregory Hundemer
MAMohsen Agharazii
Mohsen Agharazii
FMFrançois Madore
François Madore
AVAnand Vaidya
Anand Vaidya
JBJenifer M. Brown
Jenifer M. Brown
RGRémi Goupil
Rémi Goupil
BACKGROUND: Primary aldosteronism, characterized by overt renin-independent aldosterone production, is a common but underrecognized form of hypertension and cardiovascular disease. Growing evidence suggests that milder and subclinical forms of primary aldosteronism are highly prevalent, yet their contribution to cardiovascular disease is not well characterized. METHODS: This prospective study included 1284 participants between the ages of 40 and 69 years from the randomly sampled population-based CARTaGENE cohort (Québec, Canada). Regression models were used to analyze associations of aldosterone, renin, and the aldosterone-to-renin ratio with the following measures of cardiovascular health: arterial stiffness, assessed by central blood pressure (BP) and pulse wave velocity; adverse cardiac remodeling, captured by cardiac magnetic resonance imaging, including indexed maximum left atrial volume, left ventricular mass index, left ventricular remodeling index, and left ventricular hypertrophy; and incident hypertension. RESULTS: The mean (SD) age of participants was 54 (8) years and 51% were men. The mean (SD) systolic and diastolic BP were 123 (15) and 72 (10) mm Hg, respectively. At baseline, 736 participants (57%) had normal BP and 548 (43%) had hypertension. Higher aldosterone-to-renin ratio, indicative of renin-independent aldosteronism (ie, subclinical primary aldosteronism), was associated with increased arterial stiffness, including increased central BP and pulse wave velocity, along with adverse cardiac remodeling, including increased indexed maximum left atrial volume, left ventricular mass index, and left ventricular remodeling index (all P <0.05). Higher aldosterone-to-renin ratio was also associated with higher odds of left ventricular hypertrophy (odds ratio, 1.32 [95% CI, 1.002–1.73]) and higher odds of developing incident hypertension (odds ratio, 1.29 [95% CI, 1.03–1.62]). All the associations were consistent when assessing participants with normal BP in isolation and were independent of brachial BP. CONCLUSIONS: Independent of brachial BP, a biochemical phenotype of subclinical primary aldosteronism is negatively associated with cardiovascular health, including greater arterial stiffness, adverse cardiac remodeling, and incident hypertension.

1 February 2015 in Hypertension
Verified
Journal Article
Closed access
PDF file
CFCatherine Fortier
Catherine Fortier
FMFabrice Mac-Way
Fabrice Mac-Way
SDSimon Desmeules
Simon Desmeules
KMKarine Marquis
Karine Marquis
SSSacha A. De Serres
Sacha A. De Serres
MAMohsen Agharazii
Mohsen Agharazii
We hypothesized that increased aortic stiffness (central elastic artery) combined with a decrease in brachial stiffness (peripheral muscular artery) leads to the reversal of the physiological stiffness gradient (ie, mismatch), promoting end-organ damages through increased forward pressure wave transmission into the microcirculation. We, therefore, examined the effect of aortic-brachial stiffness mismatch on mortality in patients in need of dialysis. In a prospective observational study, aortic-brachial arterial stiffness mismatch (pulse wave velocity ratio) was assessed using carotid-femoral pulse wave velocity divided by carotid-radial pulse wave velocity in 310 adult patients on dialysis. After a median follow-up of 29 months, 146 (47%) deaths occurred. The hazard ratio (HR) for mortality related to PWV ratio in a Cox regression analysis was 1.43 (95% confidence interval [CI], 1.24–1.64; P <0.001 per 1 SD) and was still significant after adjustments for confounding factors, such as age, dialysis vintage, sex, cardiovascular disease, diabetes mellitus, smoking status, and weight (HR, 1.23; 95% CI: 1.02–1.49). The HRs for changes in 1 SD of augmentation index (HR, 1.35; 95% CI, 1.12–1.63), carotid-femoral pulse wave velocity (HR, 1.29; 95% CI, 1.11–1.50), and carotid-radial pulse wave velocity (HR, 0.80; 95% CI, 0.67–0.95) were statistically significant in univariate analysis, but were no longer statistically significant after adjustment for age. In conclusion, aortic-brachial arterial stiffness mismatch was strongly and independently associated with increased mortality in this dialysis population. Further studies are required to confirm these finding in lower-risk groups.